{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T09:43:41Z","timestamp":1771062221349,"version":"3.50.1"},"reference-count":50,"publisher":"Japan Epidemiological Association","issue":"1","funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"crossref","award":["H27-SHINKOGYOSEI-SHITEI-004"],"award-info":[{"award-number":["H27-SHINKOGYOSEI-SHITEI-004"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Epidemiology"],"published-print":{"date-parts":[[2022,1,5]]},"DOI":"10.2188\/jea.je20210277","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T22:07:40Z","timestamp":1635545260000},"page":"34-43","source":"Crossref","is-referenced-by-count":21,"title":["A Nationwide Epidemiological Survey of Adolescent Patients With Diverse Symptoms Similar to Those Following Human Papillomavirus Vaccination: Background Prevalence and Incidence for Considering Vaccine Safety in Japan"],"prefix":"10.2188","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3666-6942","authenticated-orcid":false,"given":"Wakaba","family":"Fukushima","sequence":"first","affiliation":[{"name":"Department of Public Health, Osaka City University Graduate School of Medicine"},{"name":"Research Center for Infectious Disease Sciences, Osaka City University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8708-3237","authenticated-orcid":false,"given":"Megumi","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Faculty of Medicine, Saga University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Division of Environmental Medicine and Population Sciences, Department of Social and Environmental Medicine, Osaka University Graduate School of Medicine, Osaka University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Pain Medicine, Osaka University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Ugawa","sequence":"additional","affiliation":[{"name":"Department of Human Neurophysiology, School of Medicine, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dokkyo Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Faculty of Human Sciences, University of Tsukuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Kusunoki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kindai University Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2080-7795","authenticated-orcid":false,"given":"Shuji","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Fujita Health University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-3483","authenticated-orcid":false,"given":"Tomotaka","family":"Sobue","sequence":"additional","affiliation":[{"name":"Division of Environmental Medicine and Population Sciences, Department of Social and Environmental Medicine, Osaka University Graduate School of Medicine, Osaka University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"991","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Arbyn M, Xu L. Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials. <i>Expert Rev Vaccines<\/i>. 2018;17(12):1085\u20131091.","DOI":"10.1080\/14760584.2018.1548282"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tabrizi SN, Brotherton JM, Kaldor JM, et\u00a0al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. <i>Lancet Infect Dis<\/i>. 2014;14(10):958\u2013966.","DOI":"10.1016\/S1473-3099(14)70841-2"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Cameron RL, Kavanagh K, Pan J, et\u00a0al. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009\u20132013. <i>Emerg Infect Dis<\/i>. 2016;22(1):56\u201364.","DOI":"10.3201\/eid2201.150736"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Simms KT, Steinberg J, Caruana M, et\u00a0al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020\u201399: a modelling study. <i>Lancet Oncol<\/i>. 2019;20(3):394\u2013407.","DOI":"10.1016\/S1470-2045(18)30836-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hanley SJ, Yoshioka E, Ito Y, Kishi R. HPV vaccination crisis in Japan. <i>Lancet<\/i>. 2015;385(9987):2571.","DOI":"10.1016\/S0140-6736(15)61152-7"},{"key":"6","unstructured":"6. World Health Organization. Global Advisory Committee on Vaccine Safety, 2\u20133 December 2015. <i>Wkly Epidemiol Rec<\/i>. 2016;91(3):21\u201331."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ueda Y, Yagi A, Ikeda S, Enomoto T, Kimura T. Beyond resumption of the Japanese Government\u2019s recommendation of the HPV vaccine. <i>Lancet Oncol<\/i>. 2018;19(12):1563\u20131564.","DOI":"10.1016\/S1470-2045(18)30573-4"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ikeda S, Ueda Y, Yagi A, et\u00a0al. HPV vaccination in Japan: what is happening in Japan? <i>Expert Rev Vaccines<\/i>. 2019;18(4):323\u2013325.","DOI":"10.1080\/14760584.2019.1584040"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ogawa Y, Takei H, Ogawa R, Mihara K. Safety of human papillomavirus vaccines in healthy young women: a meta-analysis of 24 controlled studies. <i>J Pharm Health Care Sci<\/i>. 2017;3:18.","DOI":"10.1186\/s40780-017-0087-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Setiawan D, Luttjeboer J, Pouwels KB, Wilschut JC, Postma MJ. Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis. <i>Jpn J Clin Oncol<\/i>. 2017;47(3):265\u2013276.","DOI":"10.1093\/jjco\/hyw192"},{"key":"11","unstructured":"11. Genovese C, LA Fauci V, Squeri A, Trimarchi G, Squeri R. HPV vaccine and autoimmune diseases: systematic review and meta-analysis of the literature. <i>J Prev Med Hyg<\/i>. 2018;59(3):E194\u2013E199."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Mouchet J, Salvo F, Raschi E, et\u00a0al. Human papillomavirus vaccine and demyelinating diseases a systematic review and meta-analysis. <i>Pharmacol Res<\/i>. 2018;132:108\u2013118.","DOI":"10.1016\/j.phrs.2018.04.007"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Meggiolaro A, Migliara G, La Torre G. Association between human papilloma virus (HPV) vaccination and risk of multiple sclerosis: a systematic review. <i>Hum Vaccin Immunother<\/i>. 2018;14(5):1266\u20131274.","DOI":"10.1080\/21645515.2017.1423155"},{"key":"14","unstructured":"14. Nishioka K, Yokota S, Matsumoto Y. Clinical features and preliminary diagnostic criteria of human papillomavirus vaccination associated with neuroimmunopathic syndrome (HANS). <i>Int J Rheum Dis<\/i>. 2014;17(Suppl. 2):6."},{"key":"15","unstructured":"15. Yokota S, Kuroiwa Y, Nakamura I, Nakajima T, Nishioka K. General overview and discussion on HPV vaccine associated neuropathic syndrome. <i>Jpn Med J<\/i>. 2015;4758:46\u201353 [in Japanese]."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Suzuki S, Hosono A. No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: results of the Nagoya study. <i>Papillomavirus Res<\/i>. 2018;5:96\u2013103.","DOI":"10.1016\/j.pvr.2018.02.002"},{"key":"17","unstructured":"17. National Expert Committee for Vaccine Safety, Ministry of Health, Labour and Welfare, Japan. The results of follow-up surveys among the reported patients with adverse events following human papillomavirus vaccination (Material 4-1 at the meeting held in September 17, 2015) [in Japanese]. Available at: https:\/\/www.mhlw.go.jp\/file\/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka\/0000097681.pdf. (3 June 2021, date last accessed)."},{"key":"18","unstructured":"18. Kawamura T. [A manual of a nationwide epidemiological survey for estimating the number of patients and assessing clinico-epidemiological characteristics of patients with intractable diseases (2nd edition)] [in Japanese]. The Study Group on Epidemiologic Research for Intractable Diseases. 2006. (The 3rd edition is available at following website: http:\/\/www.jichi.ac.jp\/dph\/nanbyou\/manual_2017.pdf. 3 June 2021, date last accessed)."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Nakamura Y, Matsumoto T, Tamakoshi A, et\u00a0al. Prevalence of idiopathic hypoparathyroidism and pseudohypoparathyroidism in Japan. <i>J Epidemiol<\/i>. 2000;10:29\u201333.","DOI":"10.2188\/jea.10.29"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Fukushima W, Fujioka M, Kubo T, Tamakoshi A, Nagai M, Hirota Y. Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head. <i>Clin Orthop Relat Res<\/i>. 2010;468(10):2715\u20132724.","DOI":"10.1007\/s11999-010-1292-x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Stanley M. HPV vaccination in boys and men. <i>Hum Vaccin Immunother<\/i>. 2014;10(7):2109\u20132111.","DOI":"10.4161\/hv.29137"},{"key":"22","unstructured":"22. National Expert Committee for Vaccine Safety, Ministry of Health, Labour and Welfare, Japan. Meeting minutes at the meeting held in July 4, 2014. [in Japanese]. Available at: https:\/\/www.mhlw.go.jp\/stf\/shingi2\/0000092013.html. (3 June 2021, date last accessed)."},{"key":"23","unstructured":"23. National Expert Committee for Vaccine Safety, Ministry of Health, Labour and Welfare, Japan. A nationwide epidemiological survey of adolescent patients with diverse symptoms including pain and motor dysfunction (Material 4 at the meeting held in December 26, 2016) [in Japanese]. Available at: https:\/\/www.mhlw.go.jp\/file\/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka\/0000147016.pdf. (3 June 2021, date last accessed)."},{"key":"24","unstructured":"24. National Expert Committee for Vaccine Safety, Ministry of Health, Labour and Welfare, Japan. Results from additional analyses of a nationwide epidemiological survey of adolescent patients with diverse symptoms including pain and motor dysfunction (Material 4 at the meeting held in April 10, 2017) [in Japanese]. Available at: https:\/\/www.mhlw.go.jp\/file\/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka\/0000161352.pdf. (3 June 2021, date last accessed)."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Yaju Y, Tsubaki H. Safety concerns with human papilloma virus immunization in Japan: analysis and evaluation of Nagoya City\u2019s surveillance data for adverse events. <i>Jpn J Nurs Sci<\/i>. 2019;16(4):433\u2013449.","DOI":"10.1111\/jjns.12252"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. <i>N Engl J Med<\/i>. 2007;356(19):1915\u20131927.","DOI":"10.1056\/NEJMoa061741"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Garland SM, Hernandez-Avila M, Wheeler CM, et\u00a0al; Females United to Unilaterally Reduce Endo\/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. <i>N Engl J Med<\/i>. 2007;356(19):1928\u20131943.","DOI":"10.1056\/NEJMoa061760"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Tay EH, Garland S, Tang G, et\u00a0al. Clinical trial experience with prophylactic HPV 6\/11\/16\/18 VLP vaccine in young women from the Asia-Pacific region. <i>Int J Gynaecol Obstet<\/i>. 2008;102(3):275\u2013283.","DOI":"10.1016\/j.ijgo.2008.03.021"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Paavonen J, Naud P, Salmer\u00f3n J, et\u00a0al; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. <i>Lancet<\/i>. 2009;374(9686):301\u2013314.","DOI":"10.1016\/S0140-6736(09)61248-4"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Block SL, Brown DR, Chatterjee A, et\u00a0al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. <i>Pediatr Infect Dis J<\/i>. 2010;29(2):95\u2013101.","DOI":"10.1097\/INF.0b013e3181b77906"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Medina DM, Valencia A, de Velasquez A, et\u00a0al; HPV-013 Study Group. Safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. <i>J Adolesc Health<\/i>. 2010;46(5):414\u2013421.","DOI":"10.1016\/j.jadohealth.2010.02.006"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Kim YJ, Kim KT, Kim JH, et\u00a0al. Vaccination with a human papillomavirus (HPV)-16\/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10\u201314 years. <i>J Korean Med Sci<\/i>. 2010;25(8):1197\u20131204 [Erratum in <i>J Korean Med Sci<\/i>. 2010;25(12):1831].","DOI":"10.3346\/jkms.2010.25.8.1197"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Sow PS, Watson-Jones D, Kiviat N, et\u00a0al. Safety and immunogenicity of human papillomavirus-16\/18 AS04-adjuvanted vaccine: a randomized trial in 10\u201325-year-old HIV-Seronegative African girls and young women. <i>J Infect Dis<\/i>. 2013;207(11):1753\u20131763.","DOI":"10.1093\/infdis\/jis619"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Zhu F, Li J, Hu Y, et\u00a0al. Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. <i>Hum Vaccin Immunother<\/i>. 2014;10(7):1795\u20131806.","DOI":"10.4161\/hv.28702"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Zhu FC, Hu SY, Hong Y, et\u00a0al. Efficacy, immunogenicity and safety of the AS04-HPV-16\/18 vaccine in Chinese women aged 18\u201325 years: End-of-study results from a phase II\/III, randomised, controlled trial. <i>Cancer Med<\/i>. 2019;8(14):6195\u20136211.","DOI":"10.1002\/cam4.2399"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Mikamo H, Yamagishi Y, Murata S, et\u00a0al. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: a randomized, Phase 3, placebo-controlled study. <i>Vaccine<\/i>. 2019;37(12):1651\u20131658.","DOI":"10.1016\/j.vaccine.2019.01.069"},{"key":"37","unstructured":"37. World Health Organization. Meeting of the Global Advisory Committee on Vaccine Safety, 7\u20138 June 2017. <i>Wkly Epidemiol Rec<\/i>. 2017;92(28):393\u2013402."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Arana J, Mba-Jonas A, Jankosky C, et\u00a0al. Reports of postural orthostatic tachycardia syndrome after human papillomavirus vaccination in the Vaccine Adverse Event Reporting System. <i>J Adolesc Health<\/i>. 2017;61(5):577\u2013582.","DOI":"10.1016\/j.jadohealth.2017.08.004"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K. Safety of human papillomavirus vaccines: an updated review. <i>Drug Saf<\/i>. 2018;41(4):329\u2013346.","DOI":"10.1007\/s40264-017-0625-z"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Ward D, Thorsen NM, Frisch M, Valentiner-Branth P, M\u00f8lbak K, Hviid A. A cluster analysis of serious adverse event reports after human papillomavirus (HPV) vaccination in Danish girls and young women, September 2009 to August 2017. <i>Euro Surveill<\/i>. 2019;24(19).","DOI":"10.2807\/1560-7917.ES.2019.24.19.1800380"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Barboi A, Gibbons CH, Axelrod F, et\u00a0al; American Autonomic Society. Human papillomavirus (HPV) vaccine and autonomic disorders: a position statement from the American Autonomic Society. <i>Clin Auton Res<\/i>. 2020;30(1):13\u201318.","DOI":"10.1007\/s10286-019-00608-w"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Skufca J, Ollgren J, Ruokokoski E, Lyytik\u00e4inen O, Nohynek H. Incidence rates of Guillain Barr\u00e9 (GBS), chronic fatigue\/systemic exertion intolerance disease (CFS\/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002\u20132012. <i>Papillomavirus Res<\/i>. 2017;3:91\u201396.","DOI":"10.1016\/j.pvr.2017.03.001"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Tanaka H, Fujita Y, Takenaka Y, et\u00a0al; Task Force of Clinical Guidelines for Child Orthostatic Dysregulation, Japanese Society of Psychosomatic Pediatrics. Japanese clinical guidelines for juvenile orthostatic dysregulation version 1. <i>Pediatr Int<\/i>. 2009;51(1):169\u2013179.","DOI":"10.1111\/j.1442-200X.2008.02783.x"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Chen G, Du J, Jin H, Huang Y. Postural tachycardia syndrome in children and adolescents: Pathophysiology and clinical management. <i>Front Pediatr<\/i>. 2020;8:474.","DOI":"10.3389\/fped.2020.00474"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Rossetti MG, Delvecchio G, Calati R, Perlini C, Bellani M, Brambilla P. Structural neuroimaging of somatoform disorders: A systematic review. <i>Neurosci Biobehav Rev<\/i>. 2021;122:66\u201378.","DOI":"10.1016\/j.neubiorev.2020.12.017"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. H\u00e4user W, Henningsen P. Fibromyalgia syndrome: a somatoform disorder? <i>Eur J Pain<\/i>. 2014;18(8):1052\u20131059.","DOI":"10.1002\/j.1532-2149.2014.00453.x"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Albrecht DS, Forsberg A, Sandstr\u00f6m A, et\u00a0al. Brain glial activation in fibromyalgia - A multi-site positron emission tomography investigation. <i>Brain Behav Immun<\/i>. 2019;75:72\u201383.","DOI":"10.1016\/j.bbi.2018.09.018"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Fluge \u00d8, Risa K, Lunde S, et\u00a0al. B-lymphocyte depletion in myalgic encephalopathy\/chronic fatigue syndrome. An open-label phase II study with rituximab maintenance treatment. <i>PLoS One<\/i>. 2015;10(7):e0129898.","DOI":"10.1371\/journal.pone.0129898"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Fluge \u00d8, Rekeland IG, Lien K, et\u00a0al. B-lymphocyte depletion in patients with myalgic encephalomyelitis\/chronic fatigue syndrome: A randomized, double-blind, placebo-controlled trial. <i>Ann Intern Med<\/i>. 2019;170(9):585\u2013593.","DOI":"10.7326\/M18-1451"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The biopsychosocial approach to chronic pain: scientific advances and future directions. <i>Psychol Bull<\/i>. 2007;133(4):581\u2013624.","DOI":"10.1037\/0033-2909.133.4.581"}],"container-title":["Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jea\/32\/1\/32_JE20210277\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T04:56:23Z","timestamp":1715230583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jea\/32\/1\/32_JE20210277\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,5]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2188\/jea.je20210277","relation":{},"ISSN":["0917-5040","1349-9092"],"issn-type":[{"value":"0917-5040","type":"print"},{"value":"1349-9092","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,5]]},"article-number":"JE20210277"}}